EXTEND
Support for extremely premature newborns (e.g., 22-28 weeks gestation) to improve survival and reduce severe morbidity
Key Facts
About Vitara Biomedical
Vitara Biomedical is a private, pre-revenue medical device company tackling the critical unmet need in caring for infants born extremely premature, often before 24 weeks gestation. The company's flagship technology, EXTEND, is a biologically inspired, fluid-filled environment intended to bridge the gap from the womb to the NICU, aiming to reduce mortality and severe long-term complications. Backed by leading venture capital and built on foundational research from the Children's Hospital of Philadelphia, Vitara represents a potential paradigm shift in neonatology, targeting a market with a significant human and economic burden.
View full company profile